Enzyme replacement therapy for Fabry's disease

The Lancet

Volumn 375, Issue 9725, 2010, Pages 1523-

  Waldek, Stephen ^a   Germain, Dominique P ^b   Wanner, Christoph ^c   Warnock, David G ^d  

^a SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

^b LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGALSIDASE ALFA; AGALSIDASE BETA; ANTIHYPERTENSIVE AGENT; ALPHA GALACTOSIDASE; ISOENZYME;

BLOOD PRESSURE; FABRY DISEASE; GLOMERULUS FILTRATION RATE; HUMAN; LETTER; PRIORITY JOURNAL; PROTEINURIA; PUBLICATION; DRUG EFFECT; ENZYME REPLACEMENT; NOTE;

ALPHA-GALACTOSIDASE; ENZYME REPLACEMENT THERAPY; FABRY DISEASE; GLOMERULAR FILTRATION RATE; HUMANS; ISOENZYMES;

EID: 77951533707     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)60653-8     Document Type: Letter

References (5)

1. Mehta A., Beck M., Elliott P., et al. Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data. Lancet 374 (2009) 1986-1996
2. Schiffmann R., Warnock D.G., Banikazemi M., et al. Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant 24 (2009) 2102-2111
3. Germain D., Waldek S., Banikazemi M., et al. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol 18 (2007) 1547-1557
4. Lindeman R., Tobin J., and Shock N. Longitudinal studies on the rate of decline of renal function with age. J Am Geriatr Soc 33 (1985) 278-285
5. Warnock D.G., Daina E., Remuzzi G., and West M. Enzyme replacement therapy and Fabry nephropathy. Clin J Am Soc Nephrol 5 (2010) 371-378